Literature DB >> 8353402

Tumor-associated antigens in effusions of malignant and benign origin.

A Ammon1, H Eiffert, S Reil, J H Beyer, M Droese, W Hiddemann.   

Abstract

We determined the concentration and effusion/serum ratio of mucin-like carcinoma-associated antigen (MCA) in comparison to carcinoembryonic antigen, carbohydrate antigen 19-9, cancer antigen 125, and cancer antigen 15-3 in 80 sera and 99 effusions from 64 patients with histologically confirmed malignancies (4 patients out of this group showed various effusions simultaneously, which were analyzed separately) and 31 patients with various nonneoplastic diseases. Tumor cells were detected by cytological examination in 41 effusions (60.3%) from patients with neoplastic diseases, while in another 27 cases this method failed to demonstrate the malignant origin of the effusion. Of the cytological "positive" malignant effusions 90% were also correctly identified by an elevated MCA concentration at a cutoff level of 10 U/ml, whereas only one effusion of benign origin (3%) showed a slightly elevated MCA concentration of 10.5 U/ml. In 33% of cytologically "negative" effusions of patients with neoplastic diseases, the MCA concentration was also elevated, with a maximum of 453 U/ml. Increased MCA levels in cytologically confirmed malignant effusions were not restricted to metastatic breast cancer. All 17 cytologically "positive" "non-breast cancer" effusions were correctly identified by their MCA concentrations. None of the other tumor markers reached this high sensitivity at the same level of specificity. The ratio of effusion/serum concentration of all tumor markers as well as the concentration of cancer antigen 125 in effusions was of little diagnostic value. Our results indicate that the MCA concentration in an effusion correlates very closely with its malignant origin and is superior to all the other antigens tested.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8353402     DOI: 10.1007/bf00180056

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  20 in total

1.  CA 72-4 radioimmunoassay in the diagnosis of malignant effusions. Comparison of various tumor markers.

Authors:  P Ferroni; C Szpak; J W Greiner; J F Simpson; F Guadagni; W W Johnston; D Colcher
Journal:  Int J Cancer       Date:  1990-09-15       Impact factor: 7.396

2.  [Detection of metastases in effusions from body cavities].

Authors:  P Pfitzer
Journal:  Pathologe       Date:  1984-10       Impact factor: 1.011

3.  [Diagnostic procedures in pleural effusion].

Authors:  R Loddenkemper; J Engel; H Fabel; N Konietzko; H Magnussen
Journal:  Prax Klin Pneumol       Date:  1982-11

4.  [Mucin-like carcinoma-associated antigen: sensitivity and specificity in metastatic breast cancer].

Authors:  A Ammon; H Eiffert; R Alhusen; M Weber; B Rümelin; E Groh; H Bartsch; N Marschner; G A Nagel; G Krieger
Journal:  Onkologie       Date:  1990-06

5.  Diagnostic significance of the tumour markers CEA, CA 15-3 and CA 125 in malignant effusions in breast cancer.

Authors:  K Kandylis; M Vassilomanolakis; N Baziotis; A Papadimitriou; S Tsoussis; A Ferderigou; A P Efremidis
Journal:  Ann Oncol       Date:  1990-11       Impact factor: 32.976

6.  The ovarian cancer associated antigen CA 125 in patients with pleural effusions.

Authors:  J Lindgren; P Kuusela; P E Hellström; T Pettersson; M Klockars
Journal:  Eur J Cancer Clin Oncol       Date:  1988-04

7.  [Prospective comparison of the diagnostic value of cytology and immunocytology in pleural effusion studied by thoracoscopy and biopsy].

Authors:  A Neubauer; U Thalmann; R Musch; H Grosser; R Loddenkemper; D Huhn
Journal:  Klin Wochenschr       Date:  1987-05-04

8.  Ascitic fluid analysis for the differentiation of malignancy-related and nonmalignant ascites. Proposal of a diagnostic sequence.

Authors:  A L Gerbes; D Jüngst; Y N Xie; W Permanetter; G Paumgartner
Journal:  Cancer       Date:  1991-10-15       Impact factor: 6.860

9.  The immunohistochemical reactivity of a new anti-epithelial monoclonal antibody (MAb b-12) against breast carcinoma and other normal and neoplastic human tissues.

Authors:  H R Zenklusen; C Stähli; F Gudat; J von Overbeck; J Rolink; P U Heitz
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1988

10.  Detection of malignant pleural effusions by tumor marker evaluation.

Authors:  F Pavesi; M Lotzniker; P Cremaschi; L Marbello; L Acquistapace; R Moratti
Journal:  Eur J Cancer Clin Oncol       Date:  1988-06
View more
  2 in total

1.  Value of carcinoembryonic antigen (CEA) and cholesterol assays of ascitic fluid in cases of inconclusive cytology.

Authors:  M Gulyás; A D Kaposi; G Elek; L G Szollár; A Hjerpe
Journal:  J Clin Pathol       Date:  2001-11       Impact factor: 3.411

2.  The value of serum tumour markers in the prediction of aetiology and follow up of patients with pericardial effusion.

Authors:  U Bildirici; U Celikyurt; E Acar; O Bulut; T Sahin; G Kozdag; D Ural
Journal:  Cardiovasc J Afr       Date:  2012-04       Impact factor: 1.167

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.